HER2 Support Group Forums - View Single Post - Detecting breast cancer’s fingerprint in a droplet of blood

gdpawel · 06-02-2012, 10:52 PM

Dr. Robert Nagourney
Medical and Laboratory Director
Rational Therapeutics, Inc.
Long Beach, California

A report last year described a novel application of the cell search technology developed by Veridex, LLC (a subsidiary of Johnson & Johnson) that may provide an extremely sensitive tool for the early detection of cancer. Four major cancer centers in the United States were to conduct an analysis to determine the accuracy of this method for early diagnosis.

Over recent years, it has been recognized that cancer patients circulate small numbers of tumor cells in their blood. Using microbead technology, these tumor cells can be isolated from the blood stream and characterized. The original application of the technology was a prognostic marker by which patients with breast, colorectal or prostate cancers and high levels of circulating tumor cells, fell in the “high-risk” groups.

The more recent iteration of this technique will allow investigators to not only identify but also characterize the isolated tumor cells. This provides an exciting new opportunity for early diagnosis.

As we speculate on the ramifications of this discovery, certain questions are raised. The most immediate being: What to do with the data? It has previously been suggested that many cancers arise 20 or 30 years before they are clinically detected. Malignant populations measuring in the hundreds of thousands, millions or even hundreds of millions, may still lie below the radar screen of modern diagnostic tools.

If we have the capacity to identify patients 10 or 20 years before their cancers can be clinically detected, would we then begin therapy decades before clinical disease arises? If so, what treatments will we administer? Will the early detection of cancer cells be associated with the further characterization of tumors, such that targeted agents can be utilized to eliminate these clones at their earliest inception?

We will watch the development of these clinical studies with great interest. It will be even more interesting to see how we answer the questions that arise.

06-02-2012, 10:52 PM	#2
gdpawel Senior Member Join Date: Aug 2006 Location: Pennsylvania Posts: 1,080	Circulating Tumor Cells and Early Diagnosis Dr. Robert Nagourney Medical and Laboratory Director Rational Therapeutics, Inc. Long Beach, California A report last year described a novel application of the cell search technology developed by Veridex, LLC (a subsidiary of Johnson & Johnson) that may provide an extremely sensitive tool for the early detection of cancer. Four major cancer centers in the United States were to conduct an analysis to determine the accuracy of this method for early diagnosis. Over recent years, it has been recognized that cancer patients circulate small numbers of tumor cells in their blood. Using microbead technology, these tumor cells can be isolated from the blood stream and characterized. The original application of the technology was a prognostic marker by which patients with breast, colorectal or prostate cancers and high levels of circulating tumor cells, fell in the “high-risk” groups. The more recent iteration of this technique will allow investigators to not only identify but also characterize the isolated tumor cells. This provides an exciting new opportunity for early diagnosis. As we speculate on the ramifications of this discovery, certain questions are raised. The most immediate being: What to do with the data? It has previously been suggested that many cancers arise 20 or 30 years before they are clinically detected. Malignant populations measuring in the hundreds of thousands, millions or even hundreds of millions, may still lie below the radar screen of modern diagnostic tools. If we have the capacity to identify patients 10 or 20 years before their cancers can be clinically detected, would we then begin therapy decades before clinical disease arises? If so, what treatments will we administer? Will the early detection of cancer cells be associated with the further characterization of tumors, such that targeted agents can be utilized to eliminate these clones at their earliest inception? We will watch the development of these clinical studies with great interest. It will be even more interesting to see how we answer the questions that arise.